Literature DB >> 8046429

Ribozyme mediated destruction of influenza A virus in vitro and in vivo.

X B Tang1, G Hobom, D Luo.   

Abstract

Short catalytic RNAs with inherent, specific endoribonuclease activity, called ribozymes, have recently been shown to exist in nature. According to the structural models artificial ribozymes have been designed that can potentially hydrolyse any chosen target RNA sequence in trans at a specific site. We have constructed and characterized in vitro hammerhead and hairpin ribozymes designed to cleave viral RNA segment 5 of influenza A virus. Both ribozymes were functional under optimal in vitro conditions, but quantitative measurements indicate that the hammerhead ribozyme is considerably more efficient at this target site than the hairpin ribozyme. Mg2+ dependent hammerhead ribozyme-mediated cleavage reactions were enhanced at higher temperature and in presence of spermidine, but catalytic activities were retained also in cellular extract S-100 or nuclear extracts at physiological temperatures. Recombinant plasmids derived from transfection vector pSV2-neo were engineered to allow the expression of specific ribozymes under the control of SV40 early promoter or SV40 early+ late promoters. These plasmids were introduced by transfection into COS cells, and their expression and enzymatic activities were analyzed in stable cell lines after selection of neomycin-resistance. Several permanent ribozyme-expressing clones were established and characterized: ribozyme coding DNA sequences and synthesis of ribozyme RNA molecules in the transfected cells were determined and monitored by polymerase chain reactions. It was found that the highest levels (up to 70-80%) of resistance to influenza A virus strain X-31 super-infection was observed in COS cells transfected with plasmids containing SV40 early or SV40 early+late promoters coinciding with relatively high and constitutive rates of ribozyme expression. These results suggest the feasibility of developing ribozymes designed against influenza virus to achieve therapeutic value.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8046429     DOI: 10.1002/jmv.1890420411

Source DB:  PubMed          Journal:  J Med Virol        ISSN: 0146-6615            Impact factor:   2.327


  18 in total

1.  Hammerhead ribozymes selectively suppress mutant type I collagen mRNA in osteogenesis imperfecta fibroblasts.

Authors:  P A Dawson; J C Marini
Journal:  Nucleic Acids Res       Date:  2000-10-15       Impact factor: 16.971

2.  Efficient and specific ribozyme-mediated reduction of bovine alpha-lactalbumin expression in double transgenic mice.

Authors:  P J L'Huillier; S Soulier; M G Stinnakre; L Lepourry; S R Davis; J C Mercier; J L Vilotte
Journal:  Proc Natl Acad Sci U S A       Date:  1996-06-25       Impact factor: 11.205

3.  In vitro analysis of ribozyme-mediated knockdown of an ADRP associated rhodopsin mutation.

Authors:  Dibyendu Chakraborty; Patrick Whalen; Alfred S Lewin; Muna I Naash
Journal:  Adv Exp Med Biol       Date:  2008       Impact factor: 2.622

Review 4.  Antigene, ribozyme and aptamer nucleic acid drugs: progress and prospects.

Authors:  R A Stull; F C Szoka
Journal:  Pharm Res       Date:  1995-04       Impact factor: 4.200

5.  Effective inhibition of influenza virus production in cultured cells by external guide sequences and ribonuclease P.

Authors:  D Plehn-Dujowich; S Altman
Journal:  Proc Natl Acad Sci U S A       Date:  1998-06-23       Impact factor: 11.205

Review 6.  Antiviral ribozymes. New jobs for ancient molecules.

Authors:  A Menke; G Hobom
Journal:  Mol Biotechnol       Date:  1997-08       Impact factor: 2.695

7.  Selection of the best target site for ribozyme-mediated cleavage within a fusion gene for adenovirus E1A-associated 300 kDa protein (p300) and luciferase.

Authors:  H Kawasaki; J Ohkawa; N Tanishige; K Yoshinari; T Murata; K K Yokoyama; K Taira
Journal:  Nucleic Acids Res       Date:  1996-08-01       Impact factor: 16.971

8.  Specificity of hammerhead ribozyme cleavage.

Authors:  K J Hertel; D Herschlag; O C Uhlenbeck
Journal:  EMBO J       Date:  1996-07-15       Impact factor: 11.598

Review 9.  Message therapy: gene therapy that targets mRNA sequence and stability.

Authors:  K F Kozarsky; L A Couture
Journal:  Am J Hum Genet       Date:  1997-10       Impact factor: 11.025

10.  Nucleic acid-mediated cleavage of M1 gene of influenza A virus is significantly augmented by antisense molecules targeted to hybridize close to the cleavage site.

Authors:  B Kumar; Madhu Khanna; P Kumar; V Sood; R Vyas; A C Banerjea
Journal:  Mol Biotechnol       Date:  2012-05       Impact factor: 2.695

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.